Dynavax Technologies Revenue 2010-2022 | DVAX

Dynavax Technologies revenue from 2010 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Dynavax Technologies Annual Revenue
(Millions of US $)
2021 $439
2020 $47
2019 $35
2018 $8
2017 $0
2016 $11
2015 $4
2014 $11
2013 $11
2012 $10
2011 $22
2010 $24
2009 $40
Dynavax Technologies Quarterly Revenue
(Millions of US $)
2022-03-31 $114
2021-12-31 $195
2021-09-30 $108
2021-06-30 $53
2021-03-31 $83
2020-12-31 $20
2020-09-30 $13
2020-06-30 $3
2020-03-31 $11
2019-12-31 $11
2019-09-30 $11
2019-06-30 $8
2019-03-31 $6
2018-12-31 $5
2018-09-30 $1
2018-06-30 $1
2018-03-31 $0
2017-12-31 $0
2017-09-30 $0
2017-06-30 $0
2017-03-31 $0
2016-12-31 $7
2016-09-30 $0
2016-06-30 $3
2016-03-31 $1
2015-12-31 $1
2015-09-30 $1
2015-06-30 $2
2015-03-31 $1
2014-12-31 $2
2014-09-30 $2
2014-06-30 $3
2014-03-31 $3
2013-12-31 $3
2013-09-30 $3
2013-06-30 $3
2013-03-31 $2
2012-12-31 $2
2012-09-30 $3
2012-06-30 $3
2012-03-31 $2
2011-12-31 $11
2011-09-30 $1
2011-06-30 $7
2011-03-31 $2
2010-12-31 $2
2010-09-30 $12
2010-06-30 $2
2010-03-31 $8
2009-12-31 $2
2009-09-30 $3
2009-06-30 $16
2009-03-31 $19
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.570B $0.439B
Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.107B 9.86
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.761B 16.99
Biohaven Pharmaceutical Holding (BHVN) United States $10.111B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.648B 0.00
Emergent Biosolutions (EBS) United States $1.770B 7.57
Arcus Biosciences (RCUS) United States $1.376B 34.89
Myovant Sciences (MYOV) United Kingdom $1.033B 0.00
Zymeworks (ZYME) Canada $0.397B 0.00
Gelesis Holdings (GLS) United States $0.345B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
Enzo Biochem (ENZ) United States $0.110B 22.60
SQZ Biotechnologies (SQZ) United States $0.100B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00